Actinium Pharmaceuticals Inc ATNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
-
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
Trading Information
- Previous Close Price
- $1.80
- Day Range
- $1.78–1.84
- 52-Week Range
- $1.33–10.24
- Bid/Ask
- $1.77 / $1.81
- Market Cap
- $55.77 Mil
- Volume/Avg
- 275,543 / 815,882
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 621.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.actiniumpharma.com
Comparables
Valuation
Metric
|
ATNM
|
PSTX
|
ACRV
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.25 | 4.73 | 1.04 |
Price/Sales | 621.53 | 3.19 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ATNM
|
PSTX
|
ACRV
|
---|---|---|---|
Quick Ratio | 8.84 | 2.44 | 16.00 |
Current Ratio | 8.95 | 2.48 | 16.16 |
Interest Coverage | — | −11.50 | — |
Quick Ratio
ATNM
PSTX
ACRV
Profitability
Metric
|
ATNM
|
PSTX
|
ACRV
|
---|---|---|---|
Return on Assets (Normalized) | −42.47% | −33.29% | −34.86% |
Return on Equity (Normalized) | −86.13% | −92.95% | −38.09% |
Return on Invested Capital (Normalized) | −91.06% | −46.70% | −36.96% |
Return on Assets
ATNM
PSTX
ACRV
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Fgmgfvmbxx | Dbzq | $554.5 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Xvynsnt | Wdvpkx | $119.6 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Rblpjvv | Zjxpkq | $114.6 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Tzxbypjh | Rxxnww | $35.2 Bil | |||
argenx SE ADR
ARGX
| Cpqfsmyg | Gyqzw | $31.7 Bil | |||
BioNTech SE ADR
BNTX
| Stclwctl | Hwjz | $28.0 Bil | |||
Moderna Inc
MRNA
| Gbxwhhkxt | Rgfz | $24.6 Bil | |||
United Therapeutics Corp
UTHR
| Srrcbvqht | Zddv | $15.9 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Rwpfzbz | Pxbsmv | $13.4 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Nqtdqyxmy | Knmhqh | $12.6 Bil |